Hepatitis B vaccination of 113 hemophiliacs: Lower antibody response in anti‐LAV/HTLV‐III‐positive patients

Zanetti, Alessandro; Mannucci, Pier Mannuccio; Tanzi, Elisabetta; Moroni, Gian Alessandro; Paschale, Massimo De; Morfini, Massimo; Carnelli, V.; Tirindelli, Maria Cristina; Biasi, R. De; Ciavarella, N.; Rosa, Veronica De; Rodeghiero, Francesco; Colombo, Massimo

doi:10.1002/ajh.2830230406

Cited by 37 publications

(19 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Immunization for hepatitis B in HIV-infected CKD patients is more important because not only does HBV infection occur more frequently with HIV infection for behavioral reasons, but also because the pre-HAART studies suggested that these patients are more likely to develop chronic infection [105]. However, several reports have suggested that antibody response to hepatitis vaccination is impaired in HIV-infected patients [106, 107, 108]. Although hepatitis vaccination may increase plasma viral load, the effect is minimal and transient and is unlikely to be of clinical relevance [109, 110].…”

Section: Vaccinationmentioning

confidence: 99%

Dialyzing a Patient with Human Immunodeficiency Virus Infection: What a Nephrologist Needs to Know

Mandayam

Ahuja

2004

Am J Nephrol

View full text Add to dashboard Cite

The percentage of dialysis centers that have reported dialyzing human immunodeficiency virus (HIV)-infected patients increased from 11% in 1985 to 37% in 2000. Being primary care physicians for the dialysis patients, nephrologists are frequently confronted with the management of HIV-infected dialysis patients especially in urban centers. The aims of the present review are to discuss issues that are unique to HIV infection and end-stage renal disease, and to provide dialysis caretakers with sufficient information to help them optimize care and improve outcomes of these patients. Issues related to the choice of renal replacement therapy, vascular access, management of anemia, vaccination, and antiretroviral therapies are discussed in detail.

show abstract

Section: Vaccinationmentioning

confidence: 99%

Dialyzing a Patient with Human Immunodeficiency Virus Infection: What a Nephrologist Needs to Know

Mandayam

Ahuja

2004

Am J Nephrol

View full text Add to dashboard Cite

show abstract

“…The failure to seroconvert and a more rapid loss of immune titre has been reported by other investigators analysing data from haemophiliac populations and other HIV+ groups [4,5,10,14]. The association of loss of HBsAb with higher CD4+ counts and younger age in the HIV+ subjects is unexplained.…”

Section: Discussionmentioning

confidence: 71%

Changes in hepatitis B serologic titers in HIV+ and HIV– children with haemophilia

et al. 1999

View full text Add to dashboard Cite

This longitudinal study examines differences in hepatitis B immune titres in children and adolescents with haemophilia to determine if they are dependent on how immunity was acquired (vaccination or natural infection), and whether they are related to the child's HIV status and/or are influenced by HIV disease progression. Serologic titres (HBcAb, HBsAb) and HBsAg were measured prospectively at baseline, and at years 1, 2 and 3 of follow-up in 126 HIV- and 207 HIV+ children and adolescents with haemophilia. Analyses were performed to assess the impact of HIV status on the measured titres, and for HIV+ subjects to examine the association with CD4+ lymphocyte counts and p24 antigen status. The results show that HIV+ children were more likely than HIV- children to lose vaccine-induced immunity as indicated by the loss of HBsAb. There was an increased risk of losing HBsAb with higher CD4+ counts and younger age. Re-immunization was not successful in seven of eight HIV+ children. Two subjects (one HIV+, one HIV-) entered the study HBsAg- but became HBsAg+ over the course of follow-up. Seven HIV+ subjects lost natural immunity as indicated by the loss of HBcAb. The loss of either HBsAb or HBcAb in HIV--subjects was negligible to absent. In conclusion, because of the loss of immunity in HIV+ children the viral safety of factor replacement concentrates for these children is an important consideration. HIV- children rarely lose immunity, therefore frequent measures of HBsAb are not necessary.

show abstract

“…Zanetti, et al . found that hepatitis B vaccination resulted in the development of antibodies to hepatitis B surface antigen in 98% of haemophilia patients immunized SQ . Conversely, Fessard, et al .…”

Section: Discussionmentioning

confidence: 94%

“…They found SQ injection to be as effective as IM in inducing immunity in their population [20]. Zanetti, et al found that hepatitis B vaccination resulted in the development of antibodies to hepatitis B surface antigen in 98% of haemophilia patients immunized SQ [7]. Conversely, Fessard, et al found that antibody response was higher when vaccination was given IM [5].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Hepatitis B vaccination is effective by subcutaneous route in children with bleeding disorders: a universal data collection database analysis

et al. 2014

View full text Add to dashboard Cite

Summary Subcutaneous (SQ) vs. intramuscular (IM) vaccination may cause fewer injection site complications in children with bleeding disorders, but little is known about comparative immunogenicity. To compare immunogenicity of hepatitis B virus (HBV) vaccination administered SQ or IM to individuals <2 years old with bleeding disorders, we performed a retrospective analysis of HBV surface antibody titres among patients enrolled in the universal data collection database who had received three doses of HBV vaccine solely by one route (SQ or IM). Data reviewed were from an initial visit before 24 months of age, until time of hepatitis antibody titre testing. The SQ and IM study groups did not differ in demographics, haemophilia type or severity or bleeding history. The mean age at the time of HBV surface antibody (anti-HBs) testing was 56.9 ± 20.3 months. Eighty-five of 92 subjects (92.4%) who received vaccine SQ developed a positive antibody titre (>12 IU/L), compared to 101/114 (88.6%) who received IM (P = 0.30). There was no statistically significant difference in distribution of titre values. The average age of the subjects at time of testing was 53 ± 20 months in the SQ group vs. 60 ± 20 months in the IM group (P = 0.02). The average time between the last dose of vaccine and anti-HBs testing was 47.6 ± 18.5 months among SQ vaccinated subjects vs. 51.6 ± 20.5 months in the IM group (P = 0.2). Immunogenicity to hepatitis B vaccination by the SQ and IM routes is similar.

show abstract

Hepatitis B vaccination of 113 hemophiliacs: Lower antibody response in anti‐LAV/HTLV‐III‐positive patients

Cited by 37 publications

References 20 publications

Dialyzing a Patient with Human Immunodeficiency Virus Infection: What a Nephrologist Needs to Know

Dialyzing a Patient with Human Immunodeficiency Virus Infection: What a Nephrologist Needs to Know

Changes in hepatitis B serologic titers in HIV+ and HIV– children with haemophilia

Hepatitis B vaccination is effective by subcutaneous route in children with bleeding disorders: a universal data collection database analysis

Contact Info

Product

Resources

About